Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?

Urological Research

Volumn 40, Issue 2, 2012, Pages 95-112

  Khan, Saeed R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Diabetes; Hypertension; Metabolic syndrome; Nephrolithiasis; Oxidative stress

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANGIOTENSIN II; CALCIUM OXALATE; CALCIUM PHOSPHATE; CREATININE; CYTOSOLIC PHOSPHOLIPASE A2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OSTEOPONTIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; ULINASTATIN; URIC ACID;

ATHEROSCLEROSIS; BODY MASS; CALCIUM OXALATE STONE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; CRYSTALLIZATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENCE RISK; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STONE FORMATION; URIC ACID STONE;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X; NEPHROLITHIASIS; OBESITY; OXIDATIVE STRESS;

EID: 84863717109     PISSN: 03005623     EISSN: 14340879     Source Type: Journal    
DOI: 10.1007/s00240-011-0448-9     Document Type: Review

References (201)

1. Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848
2. Stamatelou KK, Francis ME, Jones CA et al (2003) Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63:1817
3. Soucie JM, Coates RJ, McClellan W et al (1996) Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol 143:487
4. Brikowski TH, Lotan Y, Pearle MS (2008) Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci USA 105:9841
5. Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257
6. Lieske JC, de la Vega LS, Gettman MT et al (2006) Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis 48:897
7. Jeong IG, Kang T, Bang JK et al (2011) Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 58:383
8. Saucier NA, Sinha MK, Liang KV et al (2009) Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 55:61
9. Coe FL, Evan AP, Worcester EM et al (2010) Three pathways for human kidney stone formation. Urol Res 38:147
10. Johri N, Cooper B, Robertson W et al (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116:c159
11. Tibblin G (1965) A population study of 50-year-old men. An analysis of the non-participation group. Acta Med Scand 178:453
12. Cirillo M, Laurenzi M (1988) Elevated blood pressure and positive history of kidney stones: results from a populationbased study. J Hypertens Suppl 6:S485
13. Cappuccio FP, Strazzullo P, Mancini M (1990) Kidney stones and hypertension: population based study of an independent clinical association. BMJ 300:1234
14. Kim YJ, Park MS, Kim WT et al (2010) Hypertension influences recurrent stone formation in nonobese stone formers. Urology 77:1059
15. Cappuccio FP, Siani A, Barba G et al (1999) A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens 17:1017
16. Strazzullo P, Barba G, Vuotto P et al (2001) Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol Dial Transplant 16:2232
17. Madore F, Stampfer MJ, Rimm EB et al (1998) Nephrolithiasis and risk of hypertension. Am J Hypertens 11:46
18. Madore F, Stampfer MJ, Willett WC et al (1998) Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis 32:802
19. Borghi L, Meschi T, Guerra A et al (1999) Essential arterial hypertension and stone disease. Kidney Int 55:2397
20. Stoller ML, Low RK, Shami GS et al (1996) High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall's plaque formation. J Urol 156:1263
21. Wexler BC, McMurtry JP (1981) Kidney and bladder calculi in spontaneously hypertensive rats. Br J Exp Pathol 62:369
22. Koletsky S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129
23. Domingos F, Serra A (2010) Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant 26:864
24. Akoudad S, Szklo M, McAdams MA et al (2010) Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med 51:416
25. Gillen DL, Coe FL, Worcester EM (2005) Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis 46:263
26. Breslau NA, Pak CY (1982) Endocrine aspects of nephrolithiasis. Spec Top Endocrinol Metab 3:57
27. Liu JG, Hu M, He XQ (1989) Risk factors for the formation of urinary calcium-containing stones in diabetics. Zhonghua Nei Ke Za Zhi 28:649
28. Meydan N, Barutca S, Caliskan S et al (2003) Urinary stone disease in diabetes mellitus. Scand J Urol Nephrol 37:64
29. Taylor EN, Stampfer MJ, Curhan GC (2005) Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68:1230
30. Pak CY, Sakhaee K, Moe O et al (2003) Biochemical profile of stone-forming patients with diabetes mellitus. Urology 61:523
31. Daudon M, Traxer O, Conort P et al (2006) Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17:2026
32. Zimmerer T, Weiss C, Hammes HP et al (2009) Evaluation of urolithiasis: a link between stone formation and diabetes mellitus? Urol Int 82:350
33. Eisner BH, Porten SP, Bechis SK et al (2010) Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol 183:2244
34. Hamano S, Nakatsu H, Suzuki N et al (2005) Kidney stone disease and risk factors for coronary heart disease. Int J Urol 12:859
35. Ljunghall S, Hedstrand H (1976) Renal stones and coronary heart disease. Acta Med Scand 199:481
36. Rule AD, Bergstralh EJ, Melton LJ 3rd et al (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804
37. Rule AD, Roger VL, Melton LJ 3rd et al (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 21:1641
38. Reiner AP, Kahn A, Eisner BH et al (2011) Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 185:920
39. Gupta M, Bolton DM, Gupta PN et al (1994) Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. J Urol 152:1086
40. Goel MC, Ahlawat R, Kumar M et al (1997) Chronic renal failure and nephrolithiasis in a solitary kidney: role of intervention. J Urol 157:1574
41. Gillen DL, Worcester EM, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67:685
42. Vupputuri S, Soucie JM, McClellan W et al (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222
43. Ingsathit A, Thakkinstian A, Chaiprasert A et al (2010) Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 25:1567
44. Meneses JA, Lucas FM, Assuncao FC et al (2011) The impact of metaphylaxis of kidney stone disease in the renal function at long term in active kidney stone formers patients. Urol Res [Epub ahead of print]
45. Dandona P, Aljada A, Chaudhuri A et al (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448
46. Curhan GC, Willett WC, Rimm EB et al (1998) Body size and risk of kidney stones. J Am Soc Nephrol 9:1645
47. Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293:455
48. West B, Luke A, Durazo-Arvizu RA et al (2008) Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 51:741
49. Ando R, Suzuki S, Nagaya T et al (2011) Impact of insulin resistance, insulin and adiponectin on kidney stones in the Japanese population. Int J Urol 18:131
50. Ferder L, Ferder MD, Inserra F (2010) The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 12:105
51. Jalal DI, Smits G, Johnson RJ et al (2010) Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 21:1543
52. Taylor EN, Curhan GC (2008) Fructose consumption and the risk of kidney stones. Kidney Int 73:207
53. Robertson WG (2003) A risk factor model of stone-formation. Front Biosci 8:s1330
54. Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847
55. Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450
56. Cameron MA, Maalouf NM, Adams-Huet B et al (2006) Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 17:1422
57. Strazzullo P, Mancini M (1994) Hypertension, calcium metabolism, and nephrolithiasis. Am J Med Sci 307(Suppl 1):S102
58. Timio F, Kerry SM, Anson KM et al (2003) Calcium urolithiasis, blood pressure and salt intake. Blood Press 12:122
59. Taylor EN, Curhan GC (2006) Body size and 24-hour urine composition. Am J Kidney Dis 48:905
60. Mente A, Honey RJ, McLaughlin JM et al (2006) High urinary calcium excretion and genetic susceptibility to hypertension and kidney stone disease. J Am Soc Nephrol 17:2567
61. Schleicher MM, Reis MC, Costa SS et al (2009) Patients with nephrolithiasis and blood hypertension have higher calciuria than those with isolated nephrolithiasis or hypertension? Minerva Urol Nefrol 61:9
62. Eisner BH, Porten SP, Bechis SK et al (2010) Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol 183:576
63. Taylor EN, Mount DB, Forman JP et al (2006) Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 47:780
64. Maalouf NM, Cameron MA, Moe OW et al (2010) Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol 5:1277
65. Randall A (1937) The origin and growth of renal calculi. Ann Surg 105:1009
66. Carpentier X, Bazin D, Jungers P et al (2010) The pathogenesis of Randall's plaque: a papilla cartography of Ca compounds through an ex vivo investigation based on XANES spectroscopy. J Synchrotron Radiat 17:374
67. Khan SR, Finlayson B, Hackett R (1984) Renal papillary changes in patient with calcium oxalate lithiasis. Urology 23:194
68. Evan AP, Lingeman JE, Coe FL et al (2003) Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607
69. Weller RO, Nester B, Cooke SAR (1971) Calcification in the human renal papilla: an electron microscope study. J Pathol 107:211
70. Stoller ML, Meng MV, Abrahams HM et al (2004) The primary stone event: a new hypothesis involving a vascular etiology. J Urol 171:1920
71. Miller NL, Gillen DL, Williams JC Jr et al (2009) A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. BJU Int 103:966
72. Coe FL, Evan AP, Lingeman JE et al (2010) Plaque and deposits in nine human stone diseases. Urol Res 38:239
73. Evan AP, Lingeman JE, Coe FL et al (2008) Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol 28:111
74. Evan AP (2009) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25:831
75. Evan AP, Coe FL, Rittling SR et al (2005) Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 68:145
76. Evan AP, Bledsoe S, Worcester EM et al (2007) Renal interalpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int 72:1503
77. Evan A, Lingeman J, Coe FL et al (2006) Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69:1313
78. Haggit RC, Pitcock JA (1971) Renal medullary calcification: a light and electron microscopic study. J Urol 106:342
79. Cooke SAR (1970) The site of calcification in the human renal papilla. Br J Surg 57:890
80. Carpentier X, Bazin D, Combes C et al (2011) High Zn content of Randall's plaque: a mu-X-ray fluorescence investigation. J Trace Elem Med Biol 25:160
81. Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75
82. Gower LB (2008) Biomimetic model systems for investigating the amorphous precursor pathway and its role in biomineralization. Chem Rev 108:4551
83. Murshed M, McKee MD (2010) Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr Opin Nephrol Hypertens 19:359
84. Baggio B, Gambaro G, Ossi E et al (1983) Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol 129:1161
85. Huang HS, Ma MC, Chen CF et al (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123
86. Tungsanga K, Sriboonlue P, Futrakul P et al (2005) Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 33:65
87. Boonla C, Wunsuwan R, Tungsanga K et al (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35:185
88. Tsao KC, Wu TL, Chang PY et al (2007) Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 21:426
89. Mushtaq S, Siddiqui AA, Naqvi ZA et al (2007) Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta 384:41
90. Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 20:2253
91. Evan AP, Coe FL, Lingeman JE et al (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227
92. Evan AP, Lingeman J, Coe F et al (2007) Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 71:795
93. Evan AP, Lingeman JE, Coe FL et al (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576
94. Evan AP, Lingeman JE, Worcester EM et al (2010) Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int 78:310
95. Evan AP, Coe FL, Gillen D et al (2008) Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken) 291:325
96. Evan AE, Lingeman JE, Coe FL et al (2008) Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 74:223
97. Escobar C, Byer KJ, Khaskheli H et al (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180:379
98. Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64:1283
99. Umekawa T, Byer K, Uemura H et al (2005) Diphenyleneiodium (DPI) reduces oxalate ion-and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant 20:870
100. Umekawa T, Chegini N, Khan SR (2003) Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:664
101. Giachelli CM (2005) Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res 8:229
102. Thamilselvan S, Hackett RL, Khan SR (1997) Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 157:1059
103. Thamilselvan S, Hackett RL, Khan SR (1999) Cells of proximal and distal tubular origin respond differently to challenges of oxalate and calcium oxalate crystals. J Am Soc Nephrol 10(Suppl 14):S452
104. Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349
105. Khan SR, Glenton PA, Byer KJ (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int 70:914
106. Khan SR (1995) Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 23:71
107. Sumitra K, Pragasam V, Sakthivel R et al (2005) Beneficial effect of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric patients. Nephrol Dial Transplant 20:1407
108. Huang HS, Chen J, Chen CF et al (2006) Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors. Kidney Int 70:699
109. Thamilselvan S, Byer KJ, Hackett RL et al (2000) Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 164:224
110. Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31:3
111. Khand FD, Gordge MP, Robertson WG et al (2002) Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells. Free Radic Biol Med 32:1339
112. Meimaridou E, Jacobson J, Seddon AM et al (2005) Crystal and microparticle effects on MDCK cell superoxide production: oxalate-specific mitochondrial membrane potential changes. Free Radic Biol Med 38:1553
113. Cao LC, Honeyman TW, Cooney R et al (2004) Mitochondrial dysfunction is a primary event in renal cell oxalate toxicity. Kidney Int 66:1890
114. Khan SR, Khan A, Byer KJ (2011) Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant 26:1778
115. Li N, Yi FX, Spurrier JL et al (2002) Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney. Am J Physiol Renal Physiol 282:F1111
116. Geiszt M, Kopp JB, Varnai P et al (2000) Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97:8010
117. Hanna IR, Taniyama Y, Szocs K et al (2002) NAD(P)H oxidasederived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 4:899
118. Wilcox CS, Welch WJ (2001) Oxidative stress: cause or consequence
119. Shiose A, Kuroda J, Tsuruya K et al (2001) A novel superoxideproducing NAD(P)H oxidase in kidney. J Biol Chem 276:1417
120. Thamilselvan V, Menon M, Thamilselvan S (2009) Oxalateinduced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol 297:F1399
121. Thamilselvan V, Menon M, Thamilselvan S (2011) Selective Rac1 inhibition protects renal tubular epithelial cells from oxalate-induced NADPH oxidase-mediated oxidative cell injury. Urol Res [Epub ahead of print]
122. Zuo J, Khan A, Glenton PA et al (2011) Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-prolineinduced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant 26:1785
123. Wassmann S, Laufs U, Muller K et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300
124. Tsujihata M, Momohara C, Yoshioka I et al (2008) Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 180:2212
125. Toblli JE, Ferder L, Stella I et al (2001) Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. J Urol 166:275
126. Toblli JE, Ferder L, Stella I et al (2002) Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 168:1550
127. Umekawa T, Hatanaka Y, Kurita T et al (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15:635
128. Khan SR, Shevock PN, Hackett RL (1992) Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 147:226
129. de Bruijn WC, Boeve ER, van Run PR et al (1995) Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 9:103
130. de Water R, Noordermeer C, van der Kwast TH et al (1999) Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis 33:761
131. McKee MD, Nanci A, Khan SR (1995) Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913
132. Umekawa T, Tsuji H, Uemura H et al (2009) Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104:115
133. Rashed T, Menon M, Thamilselvan S (2004) Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am J Nephrol 24:557
134. Koul HK, Menon M, Chaturvedi LS et al (2002) COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells. J Biol Chem 277:36845
135. Chaturvedi LS, Koul S, Sekhon A et al (2002) Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 277:13321
136. Toblli JE, Cao G, Casas G et al (2005) NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system. Urol Res 33:358
137. Jonassen JA, Cao LC, Honeyman T et al (2003) Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit Rev Eukaryot Gene Expr 13:55
138. Umekawa T, Chegini N, Khan SR (2002) Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int 61:105
139. Umekawa T, Iguchi M, Uemura H et al (2006) Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int 98:656
140. Iida S, Peck AB, Byer KJ et al (1999) Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. J Urol 162:1480
141. Iida S, Peck AB, Johnson-Tardieu J et al (1999) Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 10:986
142. Grewal JS, Tsai JY, Khan SR (2005) Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 387:609
143. Moriyama MT, Glenton PA, Khan SR (2001) Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 165:1687
144. Suzuki K, Tanaka T, Miyazawa K et al (1999) Gene expression of prothrombin in human and rat kidneys: basic and clinical approach. J Am Soc Nephrol 10(Suppl 14):S408
145. Lieske JC, Spargo BH, Toback FG (1992) Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 148:1517
146. Mandell I, Krauss E, Millan JC (1980) Oxalate-induced acute renal failure in Crohn's disease. Am J Med 69:628
147. Wharton R, D'Agati V, Magun AM et al (1990) Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 34:116
148. Whitworth JA (2003) 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983
149. Moritz AR, Oldt MR (1937) Arteriolar sclerosis in hypertensive and non-hypertensive individuals. Am J Pathol 13:679
150. Kimmelstiel P, Wilson C (1936) Benign and malignant hypertension and nephrosclerosis: a clinical and pathological study. Am J Pathol 12:45
151. Johnson RJ, Feig DI, Nakagawa T et al (2008) Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 26:381
152. Montecucco F, Pende A, Quercioli A et al (2010) Inflammation in the pathophysiology of essential hypertension. J Nephrol 24:23
153. Rodriguez-Iturbe B, Franco M, Tapia E et al (2011) Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol [Epub ahead of print]
154. Rodriguez-Iturbe B, Vaziri ND, Johnson RJ (2008) Inflammation, angiotensin II, and hypertension. Hypertension 52:e135 (author reply e136)
155. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J et al (2004) Oxidative stress, renal infiltration of immune cells, and saltsensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286:F606
156. Stefanadi E, Tousoulis D, Androulakis ES et al (2010) Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 8:509
157. Briones AM, Touyz RM (2010) Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12:135
158. Nistala R, Whaley-Connell A, Sowers JR (2008) Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047
159. Bautista LE, Lopez-Jaramillo P, Vera LM et al (2001) Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 19:857
160. Chrysohoou C, Panagiotakos DB, Pitsavos C et al (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol 44:152
161. Sesso HD, Buring JE, Rifai N et al (2003) C-reactive protein and the risk of developing hypertension. JAMA 290:2945
162. Kurata M, Okura T, Watanabe S et al (2006) Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond) 111:319
163. Stumpf C, John S, Jukic J et al (2005) Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 23:995
164. Wilcox CS (2002) Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4:160
165. O'Connor PM, Cowley AW Jr (2010) Modulation of pressurenatriuresis by renal medullary reactive oxygen species and nitric oxide. Curr Hypertens Rep 12:86
166. Ignarro LJ, Napoli C, Loscalzo J (2002) Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90:21
167. Armas-Padilla MC, Armas-Hernandez MJ, Sosa-Canache B et al (2007) Nitric oxide and malondialdehyde in human hypertension. Am J Ther 14:172
168. Rodriguez-Iturbe B, Romero F, Johnson RJ (2007) Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis 50:655
169. Chabrashvili T, Tojo A, Onozato ML et al (2002) Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39:269
170. Schnackenberg CG, Welch WJ, Wilcox CS (1998) Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32:59
171. Zalba G, Beaumont FJ, San Jose G et al (2000) Vascular NADH/ NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35:1055
172. Grote K, Ortmann M, Salguero G et al (2006) Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc Res 71:596
173. Landmesser U, Cai H, Dikalov S et al (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511
174. Zhou MS, Hernandez Schulman I, Pagano PJ et al (2006) Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47:81
175. Tian N, Moore RS, Phillips WE et al (2008) NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 295:R1858
176. Taylor NE, Glocka P, Liang M et al (2006) NADPH oxidase in the renal medulla causes oxidative stress and contributes to saltsensitive hypertension in Dahl S rats. Hypertension 47:692
177. Kanwar YS, Sun L, Xie P et al (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6:395
178. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7:327
179. Steckelings UM, Rompe F, Kaschina E et al (2009) The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 23:693
180. Matheson A, Willcox MD, Flanagan J et al (2010) Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 26:150
181. Okonogi H, Nishimura M, Utsunomiya Y et al (2001) Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 55:357
182. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058
183. Kakehi T, Yabe-Nishimura C (2008) NOX enzymes and diabetic complications. Semin Immunopathol 30:301
184. Chung SS, Ho EC, Lam KS et al (2003) Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14:S233
185. Asaba K, Tojo A, Onozato ML et al (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67:1890
186. Etoh T, Inoguchi T, Kakimoto M et al (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 46:1428
187. Manea A (2010) NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 342:325
188. Brown BG, Zhao XQ, Chait A et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583
189. Touyz RM (2003) Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 1:91
190. Manea A, Manea SA, Gafencu AV et al (2007) Regulation of NADPH oxidase subunit p22(phox) by NF-jB in human aortic smooth muscle cells. Arch Physiol Biochem 113:163
191. Stefanadi E, Tousoulis D, Papageorgiou N et al (2010) Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem 17:1690
192. De Rosa S, Cirillo P, Paglia A et al (2010) Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 8:259
193. Rivera J, Sobey CG, Walduck AK et al (2010) Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 15:50
194. Drummond GR, Selemidis S, Griendling KK et al (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10:453
195. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 259:87
196. Kern PA, Ranganathan S, Li C et al (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745
197. Pradhan AD, Manson JE, Rifai N et al (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327
198. Furukawa S, Fujita T, Shimabukuro M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752
199. Soares AF, Guichardant M, Cozzone D et al (2005) Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 38:882
200. Silver AE, Beske SD, Christou DD et al (2007) Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 115:627
201. Otani H (2011) Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 15:1911